Gladius Capital Management LP Grows Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Gladius Capital Management LP raised its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 48.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,131 shares of the company’s stock after purchasing an additional 1,026 shares during the period. Gladius Capital Management LP’s holdings in iTeos Therapeutics were worth $34,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp increased its position in iTeos Therapeutics by 6.5% during the third quarter. Bank of New York Mellon Corp now owns 278,959 shares of the company’s stock worth $3,055,000 after buying an additional 17,090 shares in the last quarter. Panagora Asset Management Inc. lifted its holdings in iTeos Therapeutics by 20.9% in the 3rd quarter. Panagora Asset Management Inc. now owns 146,276 shares of the company’s stock valued at $1,602,000 after purchasing an additional 25,237 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of iTeos Therapeutics by 3.8% during the third quarter. Principal Financial Group Inc. now owns 152,342 shares of the company’s stock worth $1,668,000 after buying an additional 5,555 shares in the last quarter. Syon Capital LLC acquired a new position in shares of iTeos Therapeutics in the third quarter valued at approximately $135,000. Finally, Barclays PLC lifted its stake in shares of iTeos Therapeutics by 2.4% during the third quarter. Barclays PLC now owns 322,322 shares of the company’s stock valued at $3,529,000 after buying an additional 7,442 shares during the period. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Trading Down 0.1 %

Shares of iTeos Therapeutics stock traded down $0.01 during trading hours on Thursday, reaching $12.19. The stock had a trading volume of 84,546 shares, compared to its average volume of 269,939. iTeos Therapeutics, Inc. has a 1 year low of $8.20 and a 1 year high of $18.24. The firm has a market capitalization of $438.47 million, a price-to-earnings ratio of -3.87 and a beta of 1.27. The firm has a 50 day simple moving average of $11.64 and a two-hundred day simple moving average of $10.76.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.18. Sell-side analysts forecast that iTeos Therapeutics, Inc. will post -4.76 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on ITOS shares. Wedbush reiterated an “outperform” rating and issued a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th. HC Wainwright reissued a “buy” rating and issued a $44.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 7th.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.